March 4th 2022February 14th 2022 Shorla Oncology at Bio CEO & Investor conference, New York 2022 Read more at: https://www.bio.org/events/bio-ceo-investor-conference
US FDA approves Shorla’s oncology drug for T-cell leukaemiaMarch 20th 2023Read More US FDA approves Shorla’s oncology drug for T-cell leukaemia
Shorla wins FDA approval for leukaemia drugMarch 20th 2023Read More Shorla wins FDA approval for leukaemia drug
Irish-founded Shorla Oncology secures FDA approval for leukaemia drugMarch 9th 2023Read More Irish-founded Shorla Oncology secures FDA approval for leukaemia drug
Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-Cell LeukemiaMarch 9th 2023Read More Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-Cell Leukemia
We were delighted to have been a presenting company at the BIOTECH Showcase 2023 in San Francisco recently!January 16th 2023Read More We were delighted to have been a presenting company at the BIOTECH Showcase 2023 in San Francisco recently!
Join Shorla Oncology at the BIO CEO and Investor Conference 2023January 16th 2023Read More Join Shorla Oncology at the BIO CEO and Investor Conference 2023
Join Shorla Oncology at the Biotech Showcase 2023January 5th 2023Read More Join Shorla Oncology at the Biotech Showcase 2023
Our CEO part of the “Cancer Across Borders – Ireland’s Reach” Panel DiscussionDecember 12th 2022Read More Our CEO part of the “Cancer Across Borders – Ireland’s Reach” Panel Discussion
Join Shorla Oncology at CPhI Frankfurt 2022October 19th 2022Read More Join Shorla Oncology at CPhI Frankfurt 2022
